Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 4,296 put options on the company. This represents an increase of approximately 1,387% compared to the average volume of 289 put options.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Scholar Rock in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Scholar Rock in a research report on Tuesday, June 25th. Finally, BMO Capital Markets boosted their price target on shares of Scholar Rock from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $26.43.
Get Our Latest Stock Report on SRRK
Institutional Trading of Scholar Rock
Scholar Rock Stock Up 0.5 %
Shares of NASDAQ SRRK opened at $8.65 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.04 and a quick ratio of 6.04. The stock has a market capitalization of $692.26 million, a PE ratio of -4.14 and a beta of 0.82. Scholar Rock has a one year low of $6.22 and a one year high of $21.17. The business’s fifty day moving average price is $8.90 and its 200-day moving average price is $11.05.
Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same quarter in the previous year, the company earned ($0.47) EPS. On average, equities research analysts anticipate that Scholar Rock will post -2.39 EPS for the current year.
Scholar Rock Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Recommended Stories
- Five stocks we like better than Scholar Rock
- What are earnings reports?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- Business Services Stocks Investing
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- P/E Ratio Calculation: How to Assess Stocks
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.